Effective Combination Chemotherapy with Bimonthly Docetaxel and Cisplatin with or without Hematopoietic Growth Factor Support in Patients with Advanced Gastroesophageal Cancer

Publisher： Karger

E-ISSN： 1423-0232|65|3|211-217

ISSN： 0030-2414

Source： Oncology, Vol.65, Iss.3, 2003-12, pp. : 211-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 307-313

Karger

Access to resources Recommend Favorite

A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 333-340

Karger

Access to resources Recommend Favorite

Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 101-108

Karger

Access to resources Recommend Favorite

DCF versus CF for esophagus cancer

By  

DISEASES OF THE ESOPHAGUS (ELECTRONIC), Vol. 28, Iss. 2, 2015-02 ,pp. : 180-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inflammation-Based Prognostic Score Predicts Survival in Patients with Advanced Gastric Cancer Receiving Biweekly Docetaxel and S-1 Combination Chemotherapy

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 183-191

Karger

Access to resources Recommend Favorite